Current Issue


Glucose self-monitoring had no effect on glycemic control in non–insulin-treated type 2 diabetes

Although it would seem to make sense that routine glucose self-monitoring provides better outcomes, this long-held belief is not supported by the data, said an editor's note accompanying the study.

Canagliflozin may have lower risk of cardiovascular events compared to placebo, industry-funded study finds

The study found a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo, with most amputations occurring at the toe or metatarsal.

No increase in mortality with incretin-based drugs compared to other diabetes meds, review finds

The review included 189 randomized controlled trials that compared glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-2 inhibitors with placebo or other diabetes drugs in patients with type 2 diabetes.

MKSAP quiz: Intensifying therapy

This month's quiz asks readers to evaluate a 38-year-old woman with an HbA1c value of 9.1% and high function, long life expectancy, few comorbidities, good support, health literacy, and access to care.

Spotlight on insulins degludec and glargine

Recent industry-funded studies compared degludec, an ultralong-acting, once-daily basal insulin, to basal insulin glargine on outcomes including hypoglycemia, glucose control, and cardiovascular events.

HbA1c levels may overestimate mean glucose in black type 1 diabetes patients, study finds

Editorialists cautioned that the study does not suggest that HbA1c has limited utility in black patients, adding that there is a need to better understand the subgroups that may be vulnerable to discordant HbA1c and glucose measures.

Prediabetes and artificial pancreas devices

The July/August issue of ACP Internist includes articles on prediabetes and next-generation insulin pumps.

Recall, warning, and a new generic drug

Insulin cartridge holders were recalled, patients were warned about pre-owned test strips, and a generic form of rosiglitazone maleate and metformin hydrochloride was approved.